Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see how well a new cellular immunotherapy works to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
Researchers are comparing two new combination drug treatments with the standard therapy for multiple myeloma. The people in this study have multiple myeloma that is newly diagnosed. In addition, they cannot have an autologous stem cell transplant with high-dose chemotherapy.
Multiple myeloma that keeps growing after treatment can cause cancer cells to build up inside the bones. The cancer cells crowd out healthy blood cells and make abnormal proteins that cause discomfort. Researchers in this study want to find the best dose of KTX-1001 to treat multiple myeloma that grows after treatment.
The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).
The purpose of this study is to find the highest dose of the investigational immunotherapy 2141-V11 that can be given safely in people with bladder cancer that has not invaded the bladder muscle wall, has come back after BCG therapy, and will not be surgically removed. The drug 2141-V11 attaches to a protein on immune cells and activates the immune system to find and kill bladder cancer cells. It is given directly into the bladder through a catheter (flexible tube).
Researchers are doing this study to find the best dose of ziftomenib to give with standard chemotherapy in children and young adults with acute leukemia. The people in this study have acute leukemia that keeps growing or came back after treatment. In addition, their cancers have a mutation (change) in the KMT2A, NUP98, or NPM1 genes.
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
Researchers want to see how well botensilimab and balstilimab immunotherapy works in people who were treated for colorectal cancer. The people in this study were diagnosed with either colon cancer or colorectal liver metastases (cancer that spread to the liver). 
Researchers want to find the best dose of JNJ-88549968 to use in people with myeloproliferative neoplasms. Examples of these cancers include myelofibrosis and essential thrombocythemia. In addition, their cancers have a change (mutation) in the CALR gene.
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
